CHARLOTTE, N.C.--(BUSINESS WIRE)--AOM Infusion (“AOM” or “the Company”), a leading specialty infusion provider focused on intravenous immunoglobulin (“IVIG”), chronic inflammatory (CID) and specialty infusion therapy, today announced that Keyur Mehta has been named Chief Executive Officer. Christopher York will continue in his position as Chairman of the Company.
Mr. Mehta brings more than 25 years of experience in healthcare, primarily within the alternate site infusion and specialty pharma industries. He has been an entrepreneur in the infusion pharmacy and healthcare consulting spaces and has held executive roles in both public and private companies, including DaVita, Option Care Health, BioScrip and InfuScience. His expertise spans multi-site operations, strategy, business development and clinical services. Mr. Mehta holds a bachelor’s degree in Biochemistry from New York University, a bachelor’s degree in Pharmacy from St. John’s University and an MBA from Virginia Tech University.
Mr. Mehta joined AOM in 2022 as Chief Operating Officer and quickly forged a strong partnership with the Company’s executive leadership team as well as the healthcare investment team at Ridgemont Equity Partners, which acquired AOM last year. Under Mr. Mehta’s leadership, the Company has increased its payor network and expanded its therapeutic offering while continuing its growth as a leading provider of IVIG infusion therapy.
“There is a significant opportunity for AOM to further expand our services into new markets and therapies as patients increasingly opt for at-home and ambulatory treatment options,” said Mr. Mehta. “The entire team at AOM has done a remarkable job positioning the Company for success. I am energized and excited about our Company’s future and look forward to building on AOM’s exceptional track record.”
“Keyur is an experienced specialty infusion executive and we have been impressed by his operational and team building capabilities,” said Petri Lindberg, Principal at Ridgemont Equity Partners. “We look forward to continuing to execute AOM’s strategic business plan under Keyur’s leadership.”
About AOM Infusion
AOM Infusion (“AOM” or the “Company”) provides home-based intravenous immunoglobulin (“IVIG”) therapy to patients with over 80 different chronic conditions, with long-term treatment administered by skilled infusion nurses. The Company also provides support services, including pharmacy services, referral management, insurance verification and patient education and training. AOM was founded in 1994 and holds pharmacy licenses in all 50 states. https://aominfusionrx.com/
About Ridgemont Equity Partners
Ridgemont Equity Partners is a Charlotte-based middle market private equity firm that has provided buyout and growth capital to industry-leading companies in the business and tech-enabled services, industrial growth, and healthcare sectors for three decades. The principals of Ridgemont have refined a proven, industry-focused model focused on building distinctive middle market companies. For more information, please visit www.ridgemontep.com.
